The IND application covers the use of IBX’s MagSense imaging agent for staging HER2-positive breast cancer, involving about 15-20% of breast cancer cases. HER2 breast cancers are generally aggressive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results